Hemispherx and Chronix Plan Studies to Validate Technology as a Potential Diagnostic Test for CFS SAN JOSE, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- Chronix Biomedical ("Chronix") announced today ...

IRVINE, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points ...

Chronix Biomedical has announced that it will launch a new disease detection and monitoring service for cancer researchers at the upcoming 2010 ASCO Annual Meeting. The “For Investigational Use Only” ...

SAN JOSE, Calif.--(BUSINESS WIRE)--Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease ...

Enabled Chronix to Complete Proof-of-Concept Studies Confirming Its Serum DNA Biomarkers Can Accurately Detect Early Stage Cancer and to File Two Key Patents SAN JOSE, Calif.--(BUSINESS WIRE)-- ...

San Jose, California, April 6, 2010 – Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease ...

San Jose, California, June 23, 2009 – Chronix Biomedical today reported that a new study in a peer-reviewed journal further confirms the potential diagnostic and prognostic utility of using ...

SAN JOSE, Calif.--(BUSINESS WIRE)--Chronix Biomedical today announced that it is partnering with the University of Calgary to develop a commercial version of its serum DNA-based blood test for the ...

─Advanced DNA Sequencer Allows Chronix to Speed Up and Expand Development of Its Serum DNA Biomarkers for Early Diagnosis and Monitoring of Cancer and Other Chronic Diseases─ ─New Sequencing ...

Chronix Biomedical, a diagnostic test development company that has operated mostly in secret since its 2000 inception, has finally come out of its shell — publishing information on its product in ...